ClinicalTrials.gg
WithdrawnNCT05214599BESIDEUpdated Aug 23, 2024

Pharmacokinetics, Efficacy, Tolerability and Safety of Different Budesonide Oral Gel Doses in Adults' Subjects of Both Genders With Eosinophilic Esophagitis (EoE)

A Phase 2 interventional study of Budesonide Gel in Eosinophilic Esophagitis, sponsored by Bazell Pharma AG. Withdrawn. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by Bazell Pharma AG · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Business decision

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Apr 2021, registered Jan 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing budesonide in Eosinophilic Esophagitis — 1 open to participants now, 2 under way, 1 of them phase 3. Budesonide · Eosinophilic Esophagitis.

Enrollment
18th of 18
0 · median 79
Started
2021
with 2 others
Phase 2
7 of 18
none open now
Registered
15th of 18
by date
Lead sponsor
1 of 18
Bazell Pharma AG

Among the 18 studies testing budesonide in Eosinophilic Esophagitis, this one is the 18th largest by enrollment, is one of 3 that started in 2021, is one of 7 in phase 2, and was the 15th registered.

Eosinophilic Esophagitis

235 studies on the registry are indexed under Eosinophilic Esophagitis; 53 are open to participants now.

Browse Eosinophilic Esophagitis studies →

Open to participants now

1 of the 18 studies testing budesonide in Eosinophilic Esophagitis is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About budesonide

Budesonide: first FDA approval 1994 (RHINOCORT), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Eosinophilic Esophagitis studies recruiting now, 12 (29%) set no upper age limit and 27 (64%) stop at 75 or younger; 27 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing budesonide in Eosinophilic Esophagitis, or all of them as a file.
02

Study summary

A phase I/II, multicenter, double-blind, parallel, randomized trial to assess pharmacokinetics, efficacy, tolerability and safety of different budesonide oral gel doses in adults subjects of both genders with eosinophilic esophagitis (EoE)

03

Conditions studied

  • Eosinophilic Esophagitis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects able to read, understand and sign the Form (ICF) approved by Ethical Committee;
  • Male and female subjects aged between 18 and 75 years old;
  • Body weight between 60-100 kg;
  • (BMI) ≥ 18.5 and ≤ 29.9 kg/m2;
  • Non- female subjects. Childbearing potential is defined as: women (defined as 12 months of amenorrhea or more), hysterectomized women, oophorectomized (bilateral) women and/or those who underwent tubal ligation;
  • Female participants of childbearing potential who test negative for the pregnancy test on the day of administration of the first dose of the drug (Visit 1), as well as throughout the clinical trial;
  • Female participants who practice adequate or who abstain from all activities that could result in pregnancy for at least 28 days before administering the first dose of the drug (Visit 1);
  • Female participants who agree to continue adequate contraception for 1 month after administration of the last dose of the drug;
  • Participants diagnosed with EoE, verified from a combination of symptoms compatible with EoE and histological finding greater than 15 eosinophils per high-power field in at least one esophageal mucosal ;
  • Participants unresponsive to stable dose of proton-pump inhibitor (PPI).

Exclusion criteria

Exclusion Criteria:

  • Subjects with a history within the last 5 years, except from successfully treated basal cell carcinoma;
  • History of esophageal stenosis requiring dilation and/or stenosis at endoscopy not allowing to pass the endoscope;
  • Subjects with a eosinophilic gastroenteritis diagnosis (presence of eosinophilic infiltrate in gastric antrum and duodenum);
  • Subjects with a reflux esophagitis history;
  • Subject with a previous serious asthma diagnosis;
  • Subjects with a gastroesophageal tract disease that, at the investigator's discretion, is deemed as an obstacle to take part in the trial;
  • People with chronic diseases on regular drugs that, in the investigator's opinion, may interfere with the trial;
  • Medical conditions such as serious heart or lung diseases preventing the safe performance of endoscopy;
  • Subjects with conditions known to be related to esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia and hypereosinophilic syndrome;
  • Subjects who have been on oral, intranasal or systemic at least 15 days prior to trial start;
  • Smoker of having quit smoking less than 6 months ago;
  • Have a history of excessive alcohol intake for at least 6 months prior to trial start (intake of 5 or more alcoholic beverages in one day or 15 or more alcoholic beverages per week);
  • Subjects having 5 or more cups of tea or coffee per day and who cannot abstain from them for the trial period;
  • Be on inhibitors, such as ketoconazole and grapefruit juice;
  • (ECG) findings that, in the investigator's opinion, may jeopardize participation in the trial;
  • History or presence of gastrointestinal or liver disease or other condition interfering with drug absorption, distribution, excretion or metabolism;
  • Subjects with or of using any formulation components;
  • Subjects who have been part of trial protocols in the last 12 (twelve) months (CNS Resolution 251, dated August 7, 1997, item III, sub-item J);
  • Have donated blood (> 500 mL) or undergone major surgery within the 3 months prior to the ICF signature date;
  • Have been vaccinated for the 30 days prior to admission;
  • Clinical evidence of infectious process potentially contributing for dysphagia (candidiasis, cytomegalovirus (CMV), herpes);
  • Other dysphagia cause identified at endoscopy (peptic stenosis, web, ring, achalasia, esophageal neoplasm);
  • Breastfeeding subjects, who plan to become pregnant or with a positive pregnancy test during the trial;
  • Any medical condition or laboratory change that, in the investigator's opinion, may jeopardize participation in the trial.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Group 1

    Low dose

    Drug: Budesonide Gel

  • Experimental
    Group 2

    Middle dose

    Drug: Budesonide Gel

  • Experimental
    Group 3

    High dose

    Drug: Budesonide Gel

Interventions

06

What researchers measure

Primary outcomes

  1. Determination of Pharmacokinetic Profiles

    Peak Plasma Concentration (Cmax)

    Time frame: First 24 hours after a single drug dose administration

  2. Determination of Pharmacokinetic Profiles

    Area under the plasma concentration versus time curve (AUC)

    Time frame: First 24 hours after a single drug dose administration

  3. Determination of Pharmacokinetic Profiles

    Half-life (T1/2)

    Time frame: First 24 hours after a single drug dose administration

  4. Determination of Pharmacokinetic Profiles

    Oral clearance (CL/F)

    Time frame: First 24 hours after a single drug dose administration

  5. Proportion of subjects reaching a histological response

    ≤ 6 eosinophils per high power field

    Time frame: 8 weeks of treatment

  6. Improvement in dysphagia symptoms consistent with the disease

    EAT (Eating Assessment Tool) -10 questionnaire

    Time frame: 8 weeks of treatment

Secondary outcomes

  1. Assessment of non-serious and serious adverse events rate

    Time frame: Through 8 weeks

  2. Quality of life assessment of subjects

    WHOQOL-bref questionnaire

    Time frame: Through 8 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — There is not a plan to make individual participant data (IPD) available

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2021 (actual). Primary completion is estimated for Nov 2024, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2022
First posted
Jan 28, 2022
StartActual
Apr 23, 2021
Primary completionEst.
Nov 2024
CompletionEst.
Apr 2025
Last update
Aug 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05214599
Lead sponsor
Bazell Pharma AG
Responsible party
Sponsor
First posted
Jan 28, 2022
Start date
Apr 23, 2021
Primary completion
Nov 2024 (estimated)
Completion
Apr 2025 (estimated)
Last update
Aug 23, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion